论文部分内容阅读
为解决非小细胞肺癌放射治疗后期肿瘤乏氧而产生放射耐受,各国学者尝试使用乏氧细胞放疗增敏剂、高压氧疗、中子疗法以及放疗前辅助化疗等方法,但疗效无明显提高。靶向药物的出现看似能解决一定的问题,但往往对自身机体有一定的损伤,并且有同时耐受的现象发生,如何解决这些问题,是肿瘤放化疗研究热点。研究发现,肺癌患者HIF-1α及VEGF蛋白表达情况对于放射治疗中应用增敏剂及治疗方案的制定有一定的意义。文章主要对此综述。
In order to solve the problem of radioresistance caused by tumor hypoxia in non-small cell lung cancer after radiation therapy, scholars in various countries try to use hypoxic cell radiosensitizer, hyperbaric oxygen therapy, neutron therapy and adjuvant chemotherapy before radiotherapy, but the effect is not improved . The emergence of targeted drugs appears to be able to solve certain problems, but often have some damage to their own body, and at the same time the phenomenon of tolerance, how to solve these problems, cancer radiotherapy and chemotherapy research hot spots. The study found that lung cancer patients with HIF-1α and VEGF protein expression for the application of radiation therapy sensitizers and treatment of a certain significance. The article mainly summarizes this.